TipRanks
Advertisement
Advertisement

IMCR Stock Latest News

Immunocore Completes Enrollment in Phase 3 Melanoma Trial
Company AnnouncementsImmunocore Completes Enrollment in Phase 3 Melanoma Trial
3d ago
8K
IMCR
Immunocore achieves target patient enrollment in TEBE-AM clinical trial
PremiumThe Fly
Immunocore achieves target patient enrollment in TEBE-AM clinical trial
3d ago
IMCR
Immunocore reinstated with an Overweight at JPMorgan
PremiumThe Fly
Immunocore reinstated with an Overweight at JPMorgan
27d ago
IMCR
Immunocore price target raised to $43 from $40 at Morgan Stanley
PremiumThe Fly
Immunocore price target raised to $43 from $40 at Morgan Stanley
1M ago
IMCR
Immunocore reports Q2 EPS (2c), consensus 2c
PremiumThe Fly
Immunocore reports Q2 EPS (2c), consensus 2c
1M ago
IMCR
Immunocore price target raised to $35 from $34 at Mizuho
PremiumThe FlyImmunocore price target raised to $35 from $34 at Mizuho
2M ago
IMCR
Immunocore price target raised to $35 from $34 at Mizuho
Premium
The Fly
Immunocore price target raised to $35 from $34 at Mizuho
2M ago
IMCR
Immunocore presents updated results from Phase 1/2 trial of brenetafusp
Premium
The Fly
Immunocore presents updated results from Phase 1/2 trial of brenetafusp
4M ago
IMCR
Immunocore Shareholders Back All Proposals at 2026 AGM
PremiumCompany Announcements
Immunocore Shareholders Back All Proposals at 2026 AGM
4M ago
8K
IMCR
Immunocore reports Q1 EPS 25c, consensus (26c)
PremiumThe Fly
Immunocore reports Q1 EPS 25c, consensus (26c)
4M ago
IMCR
Needham’s Gil Blum Reiterates Buy on Strong Execution, Robust Pipeline and Solid Cash Runway, Keeps $75 Price Target Unchanged
PremiumRatings
Needham’s Gil Blum Reiterates Buy on Strong Execution, Robust Pipeline and Solid Cash Runway, Keeps $75 Price Target Unchanged
4M ago
IMCR
Immunocore (IMCR): KIMMTRAK’s Durable Survival Benefit in Metastatic Uveal Melanoma Underpins Sustainable Growth and $100 Buy Rating
PremiumRatings
Immunocore (IMCR): KIMMTRAK’s Durable Survival Benefit in Metastatic Uveal Melanoma Underpins Sustainable Growth and $100 Buy Rating
5M ago
IMCR
Immunocore announces five-year overall survival data for Kimmtrak
PremiumThe FlyImmunocore announces five-year overall survival data for Kimmtrak
5M ago
IMCR
Immunocore: KIMMTRAK’s Durable Leadership in Metastatic Uveal Melanoma Underpins Buy Rating and $100 Target
Premium
Ratings
Immunocore: KIMMTRAK’s Durable Leadership in Metastatic Uveal Melanoma Underpins Buy Rating and $100 Target
5M ago
IMCR
Immunocore (IMCR): Clinical Momentum, Credible Management, and Industry Visibility Support Buy Rating
Premium
Ratings
Immunocore (IMCR): Clinical Momentum, Credible Management, and Industry Visibility Support Buy Rating
5M ago
IMCR
Qualcomm, Adobe downgraded: Wall Street’s top analyst calls
PremiumThe Fly
Qualcomm, Adobe downgraded: Wall Street’s top analyst calls
6M ago
ECL
ETN
Immunocore downgraded to Hold from Buy at Jefferies
PremiumThe Fly
Immunocore downgraded to Hold from Buy at Jefferies
6M ago
IMCR
Immunocore: Strong KIMMTRAK Execution, Robust Late-Stage Pipeline, and Cash-Funded Catalysts Support Buy Rating and $100 Target
PremiumRatings
Immunocore: Strong KIMMTRAK Execution, Robust Late-Stage Pipeline, and Cash-Funded Catalysts Support Buy Rating and $100 Target
7M ago
IMCR
Immunocore: Sustained Kimmtrak Momentum and Pipeline Catalysts Support Buy Rating
PremiumRatings
Immunocore: Sustained Kimmtrak Momentum and Pipeline Catalysts Support Buy Rating
7M ago
IMCR
Immunocore reports Q4 EPS (60c), consensus (20c)
PremiumThe FlyImmunocore reports Q4 EPS (60c), consensus (20c)
7M ago
IMCR
IMCR Earnings this Week: How Will it Perform?
Premium
Pre-Earnings
IMCR Earnings this Week: How Will it Perform?
7M ago
IMCR
Immunocore price target raised to $38 from $37 at Mizuho
Premium
The Fly
Immunocore price target raised to $38 from $37 at Mizuho
7M ago
IMCR

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >